Trial Profile

A phase III clinical trial of fixed dose combination Cefepime / AAI101

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 06 Sep 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cefepime/enmetazobactam-Allecra-Therapeutics (Primary)
Indications Gram-negative infections
Focus Therapeutic Use

Most Recent Events

23 Aug 2018 According to an Allecra Therapeutics media release, trial will be executed in 19 countries and in 114 trial sites, with more than 1,000 patients involved.
23 Aug 2018 According to an Allecra Therapeutics media release, company is ready to commence this study.
16 Feb 2018 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com